SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Windlas Biotech informs about outcome of board meeting

12 Nov 2024 Evaluate

Windlas Biotech has informed that the Board of Directors at its Meeting held on Tuesday, November 12, 2024, approved the Un-audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024. In this regard it has enclosed the following: i. Un-audited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2024. ii. Limited Review Report of the Auditors on Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2024. The meeting of the Board of Directors commenced at 12.20 pm and concluded at 1.45 pm.

The above information is a part of company’s filings submitted to BSE.

Windlas Biotech Share Price

820.55 -36.30 (-4.24%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×